There is a great need to streamline the process from the tissue sample to the diagnostic lab, whether it's genomic or ...

They looked at blood samples from 41 patients with lung cancer (mostly non-small cell) treated with curative intent for stage I to III disease (mostly stage III). Median follow-up was 35 months.

Lung cancer is the most common cancer and the leading cause of cancer mortality worldwide, 1 with non–small cell lung cancer (NSCLC) accounting for nearly 85% of all lung cancers. 2 Although the ...

Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s ...

In December 2024, the FDA approved Ensacove as a first-line treatment for non-small-cell lung cancer (NSCLC) in certain adults. NSCLC is the most common type of lung cancer.

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common complication of small cell lung cancer (SCLC). Learn about how they're connected, plus diagnosis and treatment.

A new study led by investigators from Mass General Brigham trialed stereotactic (targeted) brain-directed radiation in 100 patients with small cell lung cancer and brain metastases, finding they ...

While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for ...

Lurbinectedin plus atezolizumab significantly reduced the risk of disease progression or death by 46% compared with atezolizumab alone.

Medically reviewed by Marla Anderson, MD About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of ...

During a live event, Bruna Pellini, MD, discussed IO monotherapy as a first-line option for non–small cell lung cancer with ...